biostudies-literatureDawood SNCI NIH HHS92-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC2799236biostudies-literatureUnknown28(1)PURPOSE The purpose of this study was to determine whether trastuzumab improves prognosis of women with metastatic human epidermal growth factor receptor 2 (HER2)/neu -positive breast cancer beyond that of women with HER2/neu-negative disease. PATIENTS AND METHODS Two thousand ninety-one women with metastatic breast cancer diagnosed from 1991 to 2007, with known HER2/neu status and who had not received trastuzumab in the adjuvant setting, were identified. Disease was classified into the following three groups: HER2/neu negative, HER2/neu positive without first-line trastuzumab treatment, and HER2/neu positive with first-line trastuzumab treatment. Overall survival (OS) was estimated using the Kaplan-Meier product-limit method and compared between groups with the log-rank test. Cox proportiJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.PMC27992361K07 CA109064-05K07 CA109064Dawood SBuzdar AUBroglio KHortobagyi GNGiordano SHfalsePrognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.PURPOSE The purpose of this study was to determine whether trastuzumab improves prognosis of women with metastatic human epidermal growth factor receptor 2 (HER2)/neu -positive breast cancer beyond that of women with HER2/neu-negative disease. PATIENTS AND METHODS Two thousand ninety-one women with metastatic breast cancer diagnosed from 1991 to 2007, with known HER2/neu status and who had not received trastuzumab in the adjuvant setting, were identified. Disease was classified into the following three groups: HER2/neu negative, HER2/neu positive without first-line trastuzumab treatment, and HER2/neu positive with first-line trastuzumab treatment. Overall survival (OS) was estimated using the Kaplan-Meier product-limit method and compared between groups with the log-rank test. Cox proporti2010-01-01T00:00:00Z2010 Jan2025-04-19T15:52:19.738Z2019-03-27T00:27:39ZS-EPMC27992361993392110.1200/jco.2008.19.984410.1200/JCO.2008.19.9844